New: our quarterly report on the S&P 500, read from 500 companies’ own filings and calls. Read the Q3 2026 report

Passage Bio, Inc.

PASG

Healthcare Biotechnology

EPS
n/m
Free cash flow
n/m

Quarter to September 2026, against a year earlier

3.92 0.31 +8.59%
Market cap
$11.6M
P/E
n/m
Fwd P/E
—
Dividend yield
—
F-score
n/a
ROIC
0.00%
Net debt / EBITDA
1.0×
Payout ratio
—

What it owns vs. what it owes Q3 FY2026, Sep 30, 2026

Shareholders’ equity is 0.24% of the balance sheet. What is a balance sheet?

Sep 30, 2026 · total $20.8M

Owns

$633.0KOther short-term assets
$20.2MCash & short-term investments

Funded by

$50.0KShareholders’ equity
$20.7MOther liabilities

Debt is 0.00% of the total; shareholders’ equity 0.24%.

Older periods Dec '25 Mar '26 Jun '26 Sep '26
Total current assets
47.76 34.74 25.18 20.79
Total non-current assets
14.52 1.72 — —
Total Assets
62.28 36.46 25.18 20.79
Total current liabilities
23.08 20.10 20.72 20.74
Total non-current liabilities
20.44 4.61 — —
Total liabilities
43.53 24.71 20.72 20.74
Common Equity (Total)
18.76 11.75 4.46 0.05
Shareholders Equity (Total)
18.76 11.75 4.46 0.05

Show all line items

In millions of $ except per-share values · columns are period end dates · fundamentals updated Nov 12, 2026